We are live on ! Find out more

Mid Cap Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
DFTX
26
Definium Therapeutics
DFTX
$5.1B
$5.1B $37.99 0.63%
PBLS
27
Parabilis Medicines Inc
PBLS
$4.79B
$4.79B $38.76 2.54%
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$4.77B
$4.77B $27.68 0.36%
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.71B
$4.71B $43.39 0.98%
CELC icon
30
Celcuity
CELC
$4.41B
$4.41B $90.08 3.16%
ELVN icon
31
Enliven Therapeutics
ELVN
$4.21B
$4.21B $57.45 3.23%
TLX
32
Telix Pharmaceuticals
TLX
$4.19B
$4.19B $12.34 3.01%
MANE
33
Veradermics Inc
MANE
$4.16B
$4.16B $99.67 4.01%
RLAY icon
34
Relay Therapeutics
RLAY
$4.09B
$4.09B $18.66 2.35%
TNGX icon
35
Tango Therapeutics
TNGX
$4.05B
$4.05B $24 5.73%
LEGN icon
36
Legend Biotech
LEGN
$3.87B
$3.87B $19.91 2.83%
IOVA icon
37
Iovance Biotherapeutics
IOVA
$3.82B
$3.82B $8.43 3.1%
VKTX icon
38
Viking Therapeutics
VKTX
$3.81B
$3.81B $32.70 2.91%
IDYA icon
39
IDEAYA Biosciences
IDYA
$3.7B
$3.7B $38.35 1.26%
TARS icon
40
Tarsus Pharmaceuticals
TARS
$3.63B
$3.63B $82.77 5.1%
RCUS icon
41
Arcus Biosciences
RCUS
$3.63B
$3.63B $28.49 1.96%
DYN icon
42
Dyne Therapeutics
DYN
$3.58B
$3.58B $19.19 5.51%
ABCL icon
43
AbCellera Biologics
ABCL
$3.58B
$3.58B $11.05 3.41%
DNLI icon
44
Denali Therapeutics
DNLI
$3.45B
$3.45B $21.57 2.31%
QURE icon
45
uniQure
QURE
$3.19B
$3.19B $46 0.7%
CLDX icon
46
Celldex Therapeutics
CLDX
$3.05B
$3.05B $38.78 0.87%
MBX
47
MBX Biosciences
MBX
$3.03B
$3.03B $62.91 0.13%
ARQT icon
48
Arcutis Biotherapeutics
ARQT
$3B
$3B $23.84 2.26%
IMNM icon
49
Immunome
IMNM
$2.97B
$2.97B $26.12 2.57%
GPCR icon
50
Structure Therapeutics
GPCR
$2.94B
$2.94B $41.23 2.11%
1
2
3 4

Mid Cap Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 80 mid cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $2B and $10B — worth a combined $348B.

The largest by market cap are Praxis Precision Medicines (PRAX) at $9.64B, Kymera Therapeutics (KYMR) at $9.6B and Protagonist Therapeutics (PTGX) at $9.39B.

Among institutional investors, Definium Therapeutics (DFTX) drew the most net new fund positions in Q2 2026: 148 funds opened new positions, taking total fund holders up 114 (46%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.